<unk> , marketed under the brand name Belviq is a weight-loss drug developed by Arena Pharmaceuticals. It reduces appetite by activating a type of serotonin receptor known as the 5-HT2C receptor in a region of the brain called the hypothalamus, which is known to control appetite. It was removed from the market in the United States in 2020 due to an increased risk of cancer detected in users of Belviq.
Lorcaserin
Pegvisomant
Tegaserod
Romidepsin
Nizatidine
Lansoprazole
Dexlansoprazole
Degmacyte